Spark Plug Pipe

Before the prohibition era, cannabis was commonly used as a medicinal treatment, however, it became illegal under international regulations due to its psychoactive properties derived from the marijuana compound. While marijuana provides users with cerebral-altering effects, scientific studies have linked marijuana to effectively treating a variety of medical conditions such as cancer, Parkinson’s, Alzheimer’s, arthritis, and other neurological conditions. Currently, advancements in the medical and healthcare industry are expected to accelerate the cannabis market. However, within the shortcoming years, the recreational segment is expected to overshadow the medical segment as the North American cannabis marketplace continues to mature. Nevertheless, the medical cannabis industry is still expected to be much more globally prevalent and accessible because of the numerous countries that have moved to adopt medical legislation. Now, large global markets such as Australia, Canada, Germany, Colombia, Poland, Uruguay, and Israel are all expected to contribute to the global medical cannabis market. Furthermore, countries such as the U.K. and Thailand are also exploring cannabis legalization. According to data compiled by Grand View Research, the global legal marijuana market is expected to reach USD 66.3 Billion by the end of 2025, exhibiting a CAGR of 23.9%. Blueberries Medical Corp. (OTC:BBRRF) (CNSX:BBM.CN), Tilray, Inc. (NASDAQ:TLRY), Khiron Life Sciences Corp. (OTC:KHRNF) (TSXV:KHRN.VN), PharmaCielo Ltd. (OTC:PHCEF) (TSXV:PCLO.VN), Neptune Wellness Solutions Inc. (NASDAQ:NEPT) (TSX:NEPT.TO)

Many people rely on health insurance in order to cover expenses of high-cost treatments or just to simply cover their over-the-counter prescription. According to the 2018 Current Population Survey Annual Social and Economic Supplements (CPS ASEC) and the American Community Survey (ACS), in 2017, over 91.2% Americans, or 294.6 million people, had health insurance coverage. However, medical cannabis is not currently covered by health insurers because it is still classified as a Schedule 1 controlled substance on a federal level. Most patients are required to pay out-of-pocket for their medical cannabis prescription, which can be quite costly for patients who suffer from chronic pain and require a daily dosage. And despite the growth of the cannabis industry, the prices for products remain relatively expensive for an average consumer. Depending on the quality as well as other direct factors, medical cannabis prescriptions can generally cost anywhere from USD 5 per gram to USD 20 per gram. Typically, states that passed medical cannabis legislation earlier tend to have significantly lower prices when compared to states that recently implemented medical cannabis. Moreover, different cannabis products such as concentrates, extracts, and tinctures can be much more expensive than traditional cannabis flower. The prices consumers pay are a result of numerous factors such as cultivation costs as well as federally mandated taxes and fees. Due to the overwhelming tax rate, some regions can charge an absurd amount for cannabis products. As a result, many cultivators have decided to launch operations within the Latin American region. Many chose Latin America because of the lower cultivation costs as it is significantly cheaper to grow cannabis in Colombia compared to Canada, according to Matt Karnes, Managing Partner of GreenWave Advisors, a New York-based investment firm. Karnes said that producing a gram of cannabis in Colombia can cost CAD 0.05 cents compared to CAD 1.50 in Canada. Generally, the lower wages factor heavily into the cost of cultivation in Colombia, considering the minimum wage is only CAD 1.64 per hour compared to CAD 14 per hour in Ontario. “To date in the legal cannabis industry, it’s largely been all about indoor, high-end flower as a key product category. Going forward, the growth of concentrates, edibles, and pharmaceuticals means that this will less and less be the case,” said Tom Adams, Managing Director and Principal Analyst at BDS Analytics. “Colombia’s advantages as a low-cost, outdoor growth venue will place the country’s cultivators in good stead in worldwide markets.”

Blueberries Medical Corp. (OTCQB:BBRRF) (CNSX:BBM.CN) is also listed on the Canadian Securities Exchange under the ticker (CNSX:BBM.CN). Yesterday, the Company announced, “the appointment of Ian D. Atacan CPA, CMA, MBA, B.Sc. as Chief Financial Officer, replacing interim Chief Financial Officer Chris Reid, who was contracted to assist the Company with financial oversight from inception until such time as the Company procured a permanent Chief Financial Officer. Mr. Reid will work with Mr. Atacan and the Company to support a seamless transition, and the Company would like to thank Mr. Reid for his services.

Mr. Atacan brings over 25 years of financial management experience to Blueberries, having been in leadership roles with high-growth and start-up stage organizations in both the public and private markets across various industries including cannabis, mining and oil & gas. Mr. Atacan most recently served as Chief Financial Officer of Natura Naturals Holdings Inc., a licensed Canadian cannabis producer, until its acquisition by Tilray Inc. (NASDAQ:TLRY) for $82 million in 2019 where he played an instrumental role in the completion of the strategic transaction and assisted with various core functionalities. Prior to that, Mr. Atacan served as Chief Financial Officer of Global Atomic Corporation, a TSX Venture Exchange listed uranium mining and zinc recycling company with operations in Niger and Turkey, from 2010-2018. Throughout his career, Mr. Atacan excelled in strategic corporate initiatives, shareholder value creation, and risk management. Mr. Atacan is a Chartered Professional Accountant (CPA), Certified Management Accountant (CMA) and holds a B.Sc. in Electrical and Electronics Engineering and an MBA (International Finance).

Dr. Patricio Stocker, CEO of Blueberries commented: “We are pleased to welcome Mt. Atacan as our new CFO. Mr. Atacan’s vast experience with public companies and his recent success selling Natura Naturals to Tilray will strengthen our management team significantly. His wide-ranging experience in finance and strong leadership skills will be great assets to our company.”

Mr. Atacan, CFO commented: “I’m eager to join the Blueberries team during this exciting time of growth for the company. Latin America represents a tremendous opportunity and Blueberries is well positioned to lead this next evolution of the cannabis market. I was also very impressed with the Company’s expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing and the strength of its strategic partners. Having grown Natura Naturals to the stage of being acquired, I look forward to leveraging this experience assisting Blueberries with its continued success.”

The Company has granted 100,000 compensation shares to Mr. Atacan as well as options (the “Options”) to purchase up to 900,000 common shares in the capital of the Company, pursuant to the Company’s stock option plan. The Options are exercisable at a price of $0.55 per share for a period of five years, subject to vesting.

About Blueberries Medical Corp: Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.

For our latest “Buzz on the Street” Show featuring Blueberries Medical Corp. recent corporate news, please head over to:

Additionally, Check out The Latest “Behind the Buzz” Show: Featuring Blueberries Medical Corp. COO, Camilo Villalbainterviewed on Wall Street:

Tilray, Inc. (NASDAQ:TLRY) is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids currently serving tens of thousands of patients in twelve countries spanning five continents. Tilray, Inc. recently announced that after completing an acquisition of its existing import and distribution partner Alef Biotechnology SpA (“Alef”), the company has officially relaunched as Tilray Latin America SpA (“Tilray Latin America”), a wholly-owned subsidiary of Tilray. Tilray Latin America will further strengthen Tilray’s position as a global leader in the medical cannabis market. Tilray currently has medical cannabis products available in twelve countries and operates globally through its wholly-owned subsidiaries in Australia & New Zealand, Canada, Germany, and Portugal. Tilray Latin America will import, produce and distribute Tilray branded medical cannabis products in Chile and create a hub to distribute Tilray products throughout Latin America, subject to local laws. Tilray previously announced a partnership with Alef Biotechnology in February 2017 to import and distribute Tilray products in Chile and Brazil. Alef, now Tilray Latin America, is currently licensed by the Chilean government to commercially produce medical cannabis and is planning a state-of-the-art facility to domestically produce and process medical cannabis products. Chilean law permits patients to access medical cannabis products under the supervision of a recommending physician.

Khiron Life Sciences Corp. (OTCQB:KHRNF) (TSXV:KHRN.VN) is positioned to be the dominant integrated cannabis company in Latin America. Khiron Life Sciences Corp. recently announced that it had completed the acquisition of NettaGrowth International Inc., previously announced on January 25th, 2019 and April 9th, 2019, and its wholly-owned subsidiary Dormul S.A., an Uruguayan company that has obtained the first license to produce and export medical cannabis with THC for commercialization in Uruguay. As consideration for the acquisition of NettaGrowth, Khiron has issued 8,498,821 common shares to the shareholders of NettaGrowth at a deemed price of USD 1.61 per common share. Alvaro Torres, Khiron Chief Executive Officer and Director, comments, “Closing of the acquisition of Nettagrowth represents an important milestone for Khiron. With this deal we expand our geographic footprint into a market we know well, and secure access to potential patients in Uruguay and in Southern Brazil.

PharmaCielo Ltd. (OTC:PHCEF) (TSXV:PCLO.VN) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo Ltd. recently announced that it had entered into a scheme implementation agreement pursuant to which PharmaCielo has agreed to acquire all of the issued and outstanding shares and listed options of Creso Pharma Ltd., for an aggregate purchase price of approximately AUD 122 million. Creso Pharma is a global medicinal cannabis company that specializes in research, development and production of therapeutic, nutraceutical and animal health products. “PharmaCielo’s acquisition of Creso Pharma, harnessing the synergies between us, creates a combined company that is poised to become a global powerhouse in the medicinal cannabis industry. Upon closing of the transaction, the combined company will quadruple our global footprint with presence in more than a dozen countries spanning North and Latin America, Switzerland, Europe, the Middle East, Australia and New Zealand,” said David Attard, Chief Executive Officer of PharmaCielo. “The Acquisition affords us the opportunity to bring our high-quality Colombian oil production to market immediately and expand into higher-margin, branded product sales faster by harnessing the expertise of a proven and highly engaged commercialization team possessing both an immediately available product portfolio and active international sales channels.”

Neptune Wellness Solutions Inc. (NASDAQ:NEPT) (TSX:NEPT.TO) specializes in the extraction, purification and formulation of health and wellness products. Neptune Wellness Solutions Inc. recently announced that it has received its license to process cannabis from Health Canada. The Health Canada license enables Neptune to handle dried cannabis, to manufacture and purify cannabis extracts and cannabis oil, and to sell its services to other license holders. With production activities anticipated to commence shortly at Neptune’s 50,000 sq. ft. good manufacturing practice (GMP)-certified facility in Sherbrooke, Quebec, the Company expects to be able to generate revenues from existing supply agreements and conclude additional agreements shortly. “This is a thrilling moment for Neptune as our ambition to redeploy our core competencies to exciting consumer product categories by creating and delivering differentiated formulations for the burgeoning cannabis market becomes a reality. Neptune’s long-standing scientific expertise in the formulation of natural health products supports our ability to deliver exceptional quality formulations for our business customers. The processing license granted by the agency puts us on a new growth trajectory, positioning Neptune as a provider of extracted cannabis products in this large, growing global market segment,” said Jim Hamilton, President & Chief Executive Officer of Neptune.

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For blueberries medical corp., financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

Media Contact: +1-877-601-1879Url:

View original content:


Leave a Reply

Your email address will not be published. Required fields are marked *